Home Imidazoles 356559-20-1
356559-20-1,MFCD11045307
Catalog No.:AA003MW9

356559-20-1 | 6-[2-tert-Butyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-quinoxaline

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
98+%
in stock  
$23.00   $16.00
- +
5mg
98+%
in stock  
$53.00   $37.00
- +
10mg
98+%
in stock  
$70.00   $49.00
- +
50mg
98+%
in stock  
$115.00   $81.00
- +
1g
98+%
in stock  
$912.00   $639.00
- +
5g
98%
in stock  
$2,966.00   $2,076.00
- +
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Literature
Technical Information
Catalog Number:
AA003MW9
Chemical Name:
6-[2-tert-Butyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-quinoxaline
CAS Number:
356559-20-1
Molecular Formula:
C21H21N5
Molecular Weight:
343.4249
MDL Number:
MFCD11045307
SMILES:
Cc1cccc(n1)c1[nH]c(nc1c1ccc2c(c1)nccn2)C(C)(C)C
Properties
Properties
 
Form:
Solid  
Solubility:
DMSO: ≥20mg/mL  
Storage:
Keep in dry area;2-8℃;  

Computed Properties
 
Complexity:
476  
Covalently-Bonded Unit Count:
1  
Heavy Atom Count:
26  
Hydrogen Bond Acceptor Count:
4  
Hydrogen Bond Donor Count:
1  
Rotatable Bond Count:
3  
XLogP3:
3.7  

Literature

Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.

Journal: Bioorganic & medicinal chemistry letters 20130801

Title: Helicobacter infection induces podosome assembly in primary hepatocytes in vitro.

Journal: European journal of cell biology 20120301

Title: Transforming growth factor beta receptor I inhibitor sensitizes drug-resistant pancreatic cancer cells to gemcitabine.

Journal: Anticancer research 20120301

Title: Synthesis and biological evaluation of 2-pyridyl-substituted pyrazoles and imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors.

Journal: Bioorganic & medicinal chemistry letters 20100715

Title: Synthesis and biological evaluation of 4(5)-(6-methylpyridin-2-yl)imidazoles and -pyrazoles as transforming growth factor-beta type 1 receptor kinase inhibitors.

Journal: Bioorganic & medicinal chemistry 20100615

Title: Activin-like kinase 5 (ALK5) mediates abnormal proliferation of vascular smooth muscle cells from patients with familial pulmonary arterial hypertension and is involved in the progression of experimental pulmonary arterial hypertension induced by monocrotaline.

Journal: The American journal of pathology 20090201

Title: Synthesis and biological evaluation of 5-(pyridin-2-yl)thiazoles as transforming growth factor-beta type1 receptor kinase inhibitors.

Journal: Bioorganic & medicinal chemistry letters 20080315

Title: Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20070515

Title: Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis.

Journal: The Journal of pharmacology and experimental therapeutics 20050601

Title: Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.

Journal: The Journal of biological chemistry 20020419

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Related Products of 356559-20-1
Tags:356559-20-1 Molecular Formula|356559-20-1 MDL|356559-20-1 SMILES|356559-20-1 6-[2-tert-Butyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-quinoxaline